Atea Pharmaceuticals, Inc. announced the appointment of Barbara Duncan to its Board of Directors, where she will also serve as Chair of the Audit Committee. Ms. Duncan previously served as Chief Financial Officer and Treasurer at Intercept Pharmaceuticals. Prior to her leadership role with Intercept, Ms. Duncan was Chief Financial Officer and then Chief Executive Officer at DOV Pharmaceutical, which was sold to Euthymics Bioscience.